Open Access
REVIEW
ASPASIA MANTA1, SPYRIDON KAZANAS2, STEFANOS KARAMAROUDIS3, HELEN GOGAS2, DIMITRIOS C. ZIOGAS2,*
Oncology Research, Vol.30, No.5, pp. 211-219, 2022, DOI:10.32604/or.2022.026913
Abstract Epigenetic mechanisms, such as DNA methylation and histone modifications (e.g., acetylation and
deacetylation), are strongly implicated in the carcinogenesis of various malignancies. During transcription, the
expression and functionality of coding gene products are altered following the histone acetylation and deacetylation.
These processes are regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively.
HDAC inhibitors (HDACis) have been developed as promising therapeutic agents, to limit exposure to traditional
and toxic chemotherapies and offer more alternatives for some specific malignant diseases with limited options.
Mechanistically, these agents affect many intracellular pathways, including cell cycle arrest, apoptosis and
differentiation, and their mechanism… More >
Open Access
REVIEW
SUCHITRA NISHAL1, VIKAS JHAWAT1,*, SUMEET GUPTA2, PARMITA PHAUGAT1
Oncology Research, Vol.30, No.5, pp. 221-230, 2022, DOI:10.32604/or.2022.027549
Abstract Kinase inhibitors are a significant and continuously developing division of target therapeutics. The drug
discovery and improvement efforts have examined numerous attempts to target the signaling pathway of kinases. The
Kinase inhibitors have been heralded as a game-changer in cancer treatment. For developing kinase inhibitors as a
treatment for various non-malignant disorders like auto-immune diseases, is currently undergoing extensive research.
It may be beneficial to investigate whether cell-specific kinase inhibitor administration enhances therapeutic efficacy
and decreases adverse effects. The goal of the current review is to gain insight into the role of kinase inhibitors in
facilitating effective target drug delivery… More >
Open Access
REVIEW
JIATENG ZHONG1,2, JINGYU GUO1, XINYU ZHANG1, SHUANG FENG1, WENYU DI2, YANLING WANG3,*, HUIFANG ZHU1,*
Oncology Research, Vol.30, No.5, pp. 231-242, 2022, DOI:10.32604/or.2022.027900
Abstract Lipid is a key component of plasma membrane, which plays an important role in the regulation of various cell
biological behaviors, including cell proliferation, growth, differentiation and intracellular signal transduction. Studies
have shown that abnormal lipid metabolism is involved in many malignant processes, including colorectal cancer
(CRC). Lipid metabolism in CRC cells can be regulated not only by intracellular signals, but also by various
components in the tumor microenvironment, including various cells, cytokines, DNA, RNA, and nutrients including
lipids. In contrast, abnormal lipid metabolism provides energy and nutrition support for abnormal malignant growth
and distal metastasis of CRC cells. In… More >
Open Access
ARTICLE
LI YANG1,2, KUN DENG3, ZHIQIANG MOU1,2, PINGFU XIONG1,2, JIAN WEN1,2, JING LI1,2,*
Oncology Research, Vol.30, No.5, pp. 243-258, 2022, DOI: 10.32604/or.2022.027958
Abstract Background: Considering the great heterogeneity of Hepatocellular carcinoma (HCC), more accurate
prognostic models are urgently needed. This paper combined the advantages of genomics and pathomics to construct
a prognostic model. Methods: First, we collected data from hepatocellular carcinoma patients with complete mRNA
expression profiles and clinical annotations from the TCGA database. Then, based on immune-related genes, we used
random forest plots to screen prognosis-related genes and build prognostic models. Bioinformatics was used to
identify biological pathways, evaluate the tumor microenvironment, and perform drug susceptibility testing. Finally,
we divided the patients into different subgroups according to the gene model algorithm. Pathological… More >
Login
Register
Submit a Paper
Propose a Special lssue